Atogepant for prevention of migraine


featured image

Atogepant is currently in clinical development for the prevention of migraine. Migraines can occur with or without aura. Migraine without aura is a recurrent headache disorder manifesting in attacks lasting 4-72 hours. Typical characteristics of the headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity and association with nausea and/or photophobia and phonophobia.

Indications: Migraine
Therapeutic Areas: Neurology
Year: 2022

Atogepant is currently in clinical development for the prevention of migraine. Migraines can occur
with or without aura. Migraine without aura is a recurrent headache disorder manifesting in
attacks lasting 4-72 hours. Typical characteristics of the headache are unilateral location,
pulsating quality, moderate or severe intensity, aggravation by routine physical activity and
association with nausea and/or photophobia and phonophobia. Migraine with aura consists of
recurrent attacks, lasting minutes, of unilateral fully-reversible visual, sensory or other central
nervous system symptoms that usually develop gradually and are usually followed by headache
and associated migraine symptoms. Preventative (prophylactic) treatment of migraine is used to
reduce the number of migraines a patient experiences. However, currently available treatment
options involve injections underneath the skin (subcutaneous injection), which can cause
unwanted side-effects. There remains an unmet need for prophylactic treatment options to
prevent migraine that can be given to patients without the need for subcutaneous injection.